The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM
The glucagon-like peptide-1 (GLP-1) is a peptide with incretin activity and plays an important role in glycemic control as well as the improvement of insulin resistance in type 2 diabetes mellitus (T2DM). However, the short half-life of the native GLP-1 in circulation poses difficulties for clinical...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/4/1202 |
| _version_ | 1797603896668979200 |
|---|---|
| author | Qing Wang Haixin Guo Wenwei Mao Xiuping Qian Yangang Liu |
| author_facet | Qing Wang Haixin Guo Wenwei Mao Xiuping Qian Yangang Liu |
| author_sort | Qing Wang |
| collection | DOAJ |
| description | The glucagon-like peptide-1 (GLP-1) is a peptide with incretin activity and plays an important role in glycemic control as well as the improvement of insulin resistance in type 2 diabetes mellitus (T2DM). However, the short half-life of the native GLP-1 in circulation poses difficulties for clinical practice. To improve the proteolytic stability and delivery properties of GLP-1, a protease-resistant modified GLP-1 (mGLP-1) was constructed with added arginine to ensure the structural integrity of the released mGLP-1 in vivo. The model probiotic <i>Lactobacillus plantarum</i> WCFS1 was chosen as the oral delivery vehicle with controllable endogenous genetic tools driven for mGLP-1 secretory constitutive expression. The feasibility of our design was explored in db/db mice which showed an improvement in diabetic symptoms related to decreased pancreatic glucagon, elevated pancreatic β-cell proportion, and increased insulin sensitivity. In conclusion, this study provides a novel strategy for the oral delivery of mGLP-1 and further probiotic transformation. |
| first_indexed | 2024-03-11T04:38:33Z |
| format | Article |
| id | doaj.art-b86909f63c774bb9be35e13bb79d816d |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T04:38:33Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-b86909f63c774bb9be35e13bb79d816d2023-11-17T20:54:10ZengMDPI AGPharmaceutics1999-49232023-04-01154120210.3390/pharmaceutics15041202The Oral Delivery System of Modified GLP-1 by Probiotics for T2DMQing Wang0Haixin Guo1Wenwei Mao2Xiuping Qian3Yangang Liu4School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, ChinaShanghai TriApex Biotechnology Co., Ltd., Shanghai 201315, ChinaSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, ChinaSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, ChinaSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, ChinaThe glucagon-like peptide-1 (GLP-1) is a peptide with incretin activity and plays an important role in glycemic control as well as the improvement of insulin resistance in type 2 diabetes mellitus (T2DM). However, the short half-life of the native GLP-1 in circulation poses difficulties for clinical practice. To improve the proteolytic stability and delivery properties of GLP-1, a protease-resistant modified GLP-1 (mGLP-1) was constructed with added arginine to ensure the structural integrity of the released mGLP-1 in vivo. The model probiotic <i>Lactobacillus plantarum</i> WCFS1 was chosen as the oral delivery vehicle with controllable endogenous genetic tools driven for mGLP-1 secretory constitutive expression. The feasibility of our design was explored in db/db mice which showed an improvement in diabetic symptoms related to decreased pancreatic glucagon, elevated pancreatic β-cell proportion, and increased insulin sensitivity. In conclusion, this study provides a novel strategy for the oral delivery of mGLP-1 and further probiotic transformation.https://www.mdpi.com/1999-4923/15/4/1202type 2 diabetes mellitusGLP-1<i>Lactobacillus plantarum</i> WCFS1oral delivery |
| spellingShingle | Qing Wang Haixin Guo Wenwei Mao Xiuping Qian Yangang Liu The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM Pharmaceutics type 2 diabetes mellitus GLP-1 <i>Lactobacillus plantarum</i> WCFS1 oral delivery |
| title | The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM |
| title_full | The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM |
| title_fullStr | The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM |
| title_full_unstemmed | The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM |
| title_short | The Oral Delivery System of Modified GLP-1 by Probiotics for T2DM |
| title_sort | oral delivery system of modified glp 1 by probiotics for t2dm |
| topic | type 2 diabetes mellitus GLP-1 <i>Lactobacillus plantarum</i> WCFS1 oral delivery |
| url | https://www.mdpi.com/1999-4923/15/4/1202 |
| work_keys_str_mv | AT qingwang theoraldeliverysystemofmodifiedglp1byprobioticsfort2dm AT haixinguo theoraldeliverysystemofmodifiedglp1byprobioticsfort2dm AT wenweimao theoraldeliverysystemofmodifiedglp1byprobioticsfort2dm AT xiupingqian theoraldeliverysystemofmodifiedglp1byprobioticsfort2dm AT yangangliu theoraldeliverysystemofmodifiedglp1byprobioticsfort2dm AT qingwang oraldeliverysystemofmodifiedglp1byprobioticsfort2dm AT haixinguo oraldeliverysystemofmodifiedglp1byprobioticsfort2dm AT wenweimao oraldeliverysystemofmodifiedglp1byprobioticsfort2dm AT xiupingqian oraldeliverysystemofmodifiedglp1byprobioticsfort2dm AT yangangliu oraldeliverysystemofmodifiedglp1byprobioticsfort2dm |